Inventor · disambiguated record
Shuichan Xu
Also filed as: XU SHUICHAN
26 granted patents·14 pending applications·148 citations·filing 2005–2023
95Inventor score
Top patents by PatentIndex Score
40 records- 0197US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0296US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0396US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0494US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 0593US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 0692US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 0790US10004735B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2017·Granted Jun 26, 2018·4 cites·16 claims
- 0890US9737535B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2015·Granted Aug 22, 2017·5 cites·16 claims
- 0990US9155736B2Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activitySIGNAL PHARM LLC·Filed 2013·Granted Oct 13, 2015·16 cites·6 claims
- 1089US9505764B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Nov 29, 2016·11 cites·33 claims
- 1188US9375443B2Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinibSIGNAL PHARM LLC·Filed 2013·Granted Jun 28, 2016·12 cites·4 claims
- 1285US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 1385US9555033B2Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitorsCHOPRA RAJESH·Filed 2011·Granted Jan 31, 2017·6 cites·14 claims
- 1484US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 1584US2023158035A1Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2023·Application pending·0 cites
- 1683US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 1783US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 1882US9937170B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2016·Granted Apr 10, 2018·1 cites·5 claims
- 1981US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 2075US11590139B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2021·Granted Feb 28, 2023·0 cites·52 claims
- 2174US2022273650A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2021·Application pending·0 cites
- 2271US11166950B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Nov 9, 2021·0 cites·5 claims
- 2371US2023338370A1Treatment of Cancer with TOR Kinase InhibitorsSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 2470US9557338B2Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activitySIGNAL PHARM LLC·Filed 2015·Granted Jan 31, 2017·1 cites·4 claims
- 2569US2022370580A1Cereblon-based heterodimerizable chimeric antigen receptorsCELGENE CORP·Filed 2022·Application pending·0 cites
- 2664US11331380B2Cereblon-based heterodimerizable chimeric antigen receptorsCELGENE CORP·Filed 2017·Granted May 17, 2022·0 cites·22 claims
- 2753US9795607B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 2853US2014314673A1Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 2952US9980963B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2016·Granted May 29, 2018·0 cites·11 claims
- 3050US2013245027A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3146US2013158023A1Identification of gene expression as a predictive biomarker for lkb1 statusNING YUHONG L·Filed 2012·Application pending·0 cites
- 3243US2015099754A1Treatment of cancer characterized by gene mutationsSIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 3342US2013245029A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3442US2017173024A1Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereofSIGNAL PHARM LLC·Filed 2017·Application pending·0 cites
- 3542US2013245026A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3642US2013245028A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3738US10576085B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Mar 3, 2020·0 cites·22 claims
- 3838US9623028B2Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereofSIGNAL PHARM LLC·Filed 2015·Granted Apr 18, 2017·0 cites·18 claims
- 3937US2006194262A1P27 ubiquitination assay and methods of useXU SHUICHAN·Filed 2005·Application pending·0 cites
- 4037US2012028972A1Biomarker assays for detecting or measuring inhibition of tor kinase activityWONG LILLY·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →